Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

But rather than developing in vivo gene-editing, Gilead wants to use Sangamo’s ZFN expertise in the considerably less risky field of ex-vivo gene editing. The goal is to find a faster and ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established.

An investigator-initiated trial examining YolTech Therapeutics’ in vivo gene editing-based ‘life-long cure’ for patients living with a rare genetic disorder has seen the treatment able to ...

ElevateBio will leverage artificial intelligence to expand and accelerate CRISPR discovery, design, and drug development for thousands of complex ...

Editas Medicine reports advancements in in vivo gene editing, financial results, and plans for upcoming development candidates by mid-2025. Editas Medicine, Inc. announced its progress in ...

10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 ... by using a novel in vivo CRISPR genome editing ... Researchers Discover Potential Mole Reversal Therapy in Rare Condition ...

GenScript Biotech Corp., a global biotechnology leader in life science, biologics manufacturing, synthetic biology, and cell therapies, announced an exciting investment in gene editing technology.

PH1, the most common subtype, is triggered by AGXT gene mutations and typically manifests in childhood. Patients often present with kidney stones, nephrocalcinosis, renal insufficiency ...